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Histopathologic Diagnosis and Classification of Prostate
Adenocarcinoma: Biologic Significance
Jill M. Peters, MD,* and John D. Crissman, MD+

Early diagnosis and accurate, biologically meaningful classification of prostate neoplasia remain
important goals. The relation of evolving clinicopathologic concepts of histologic appearances to
potential tumor progression is a major advance in classification of prostatic neoplasia. The criteria
for recognizing incidental or "occult" stage A-l adenocarcinomas remain problematic in diagnosis,
and focal neoplasms with little or no propensity to progression must be differentiated from cancers
with a high likelihood of aggressive behavior. Current histologic grading systems in classifying
prostate adenocarcinoma accurately identify two cancer subsets: 1) focal well differentiated tumors
which rarely progress, and 2) diffuse poorly differentiated tumors which invariably develop metastatic
disease. Unfortunately, the majority of prostatic cancers are classified in the intermediate group in
which the prognosis is variable and difficult to differentiate purely by histology. Our laboratory
recently adapted image analysis of cellular DNA quantitation—a major improvement in accurately
predicting tumor behavior, especially in the intermediate histologic grades. We and others have found
that tumors with abnormal (aneuploid) DNA content are more likely to progress than neoplasms with
normal (diploid) DNA content. (Henry Ford Hosp Med J 1989;37:8-13)

C

onfirmation of prostate carcinoma requires tissue or cellular
biopsy. When prostatic adenocarcinoma is suspected either
by clinical symptoms, palpation, or ultrasound examination, a
needle biopsy or aspirate is the most common method of tissue
sampling. When a nodule is palpated, the biopsy is directed at
the nodule. Successful tissue sampling depends on the location
and size of the nodule as well as the skill of the urologist. When
the suspected neoplasm is identified by ultrasound examination,
a guided biopsy is required. Either removal of a core of the tissue
(traditional needle biopsy) or aspiration of cellular material (aspiration biopsy) can be done. The "automatic gun" approach,
which samples multiple small tissue fragments, has become
popular recentiy, but tissue samples are smaller and provide
pathologic information in-between that of needle core and aspiration biopsies. Accurate diagnosis for aspiration biopsies depends on die skill of the aspirator, the quality of the aspirate, and
the experience of the cytopathologist. Aspiration biopsies can
be interpreted accurately, but only after considerable practice
and detaUed clinical pathologic correlation by urologist and pathologist. Needle core tissue biopsies are interpreted by surgical
pathologists and remain the standard method of diagnosing
prostatic adenocarcinoma.
Prostate adenocarcinoma is the most common cancer in elderly men. Asymptomatic occult neoplasms or prostatic nodules detectable by physical examination are found in approximately one third of men in their 70s (1). The frequency of
asymptomatic occult neoplasms increases appreciably when
histologic step sections are examined from prostates removed at
autopsy. Clearly, histologic demonstration of adenocarcinoma is
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common in males in the eighth decade or greater. These observations raise questions about the relationship of asymptomatic occult cancers and their propensity to progress to a clinically significant invasive neoplasm with metastatic potential. This spectrum of neoplastic disease behavior also raises important
clinical questions as to which prostate cancers are truly "occult," not likely to progress, and can therefore be treated in a
conservative manner, and which prostate cancers are potentially
life-threatening and require therapy, often radical in extent.

Histologic Grading
Numerous schemes describing grading systems for the classification of prostatic adenocarcinoma have been reported. The
three major groups of observations incorporated to varying degrees in these grading schemes include:
1. Cytologic or nuclear grade: This set of observations includes nuclear size (shape), chromatin content and staining pattern, and presence of nucleoli and amount of cytoplasm (nuclear/cytoplasmic ratio). These observations provide the major
criteria for diagnosis of needle aspiration biopsies and are also
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integrated into many of the proposed histologic grading
schemes.
2. Neoplastic cell organization or formation of tubules/acini:
These observations reflect the extent to which the neoplasm recapitulates normal prostate tissue organization. Generally the
greater the proportion of neoplasm forming tubules (with identifiable lumens), the better the differentiation.
3. Neoplasm growth pattem: While less commonly incorporated into grading schemes, this observation is an integral part of
the Gleason classification (2,3). The pattem in which the neoplastic cells (or glands) infiltrate the adjacent host stroma (ie,
pushing borders versus single cell invasion) is significant. Small
differentiated foci of tumor usually have well demarcated tumorhost borders. In contrast, poorly differentiated tumors commonly infiltrate as single cells or cords of cells.
Grading schemes generally utilize two of the three sets of observations described in Table 1. For example, grading schemes
described by Bocking et al (4) and by Gaeta et al (5) quantify
both the cytologic and histologic patterns deriving a tumor
score. Mostofi (6) integrates both cell features and histologic
pattem into a tumor grade, and the scheme by Brawn et al (7)
derives a grade based on the proportion of tbe tumor forming
identifiable glandular stmctures. This system is similar to the
grading scheme that has been used for many years at the Mayo
Clinic (8). The histologic grading system proposed by Gleason
et al (3) varies from the other grading schemes in two ways: 1)
tumor histologic heterogeneity is recognized, and two distinct
patterns are routinely factored into the final tumor grade or
score; and 2) the pattem of tumor growth or invasion into the
host stroma is also incorporated into the five distinct pattems or
grades recognized by these authors. Well differentiated tumors
tend to have well formed glands and "pushing" borders or well
defined tumor host-stroma interfaces. Conversely, poorly differentiated neoplasms grow as single cells or irregular infiltrating
cords with little or no evidence of gland formation.
The Gleason grading system has been embraced by the
urology community, although there is little objective evidence
that its predictive value is greater than other systems. Studies of
reproducibility in grading have suggested that the simpler systems, such as the MD Anderson scheme (7), are more reproducible (9). In a comparative study of reproducibility and predictive
value, the Mostofi (6) and Bocking (4) proposals had the best
correlation with tumor stage (9). Both grading schemes incorporate cytologic factors in deriving tumor grade.
Lack of agreement in adapting a uniform grading scheme underlines the absence of an optimum system for predicting neoplasm behavior. In general, all proposed grading systems identify the relatively rare (5% to 15%) poorly differentiated
adenocarcinomas that invariably progress, as well as the well
differentiated tumors that are unlikely to progress. Well differentiated carcinomas have well demarcated tumor borders in addition to differentiated cytology and tubular formation. The former feature requires adequate tissue to determine the volume of
tumor present and its growth pattern, parameters not always
available from needle core biopsies and invariably absent in needle aspiration biopsies. Most prostate adenocarcinomas fall into
the middle range of differentiation, some of which progress and
some which do not. Most urologists and pathologists agree that:
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Table 1
Histopathologic Grading Systems for Adenocarcinoma
of the Prostate
Grading System

Histologic Observations

Gleason (2)

1. Growth pattem including:
A. Formation of tubules and acini
B. Tumor-host-stroma interface
2. Selected cytologic changes (eg. hypemephroid
appearance, central comedo-like necrosis)
3. Primary and secondary pattem scores combined for
total of nine grades

Mostofi (6)

Three grades dependent on:
1. Proportion of glandular differentiation
2. Nuclear anaplasia

Bocking (4)

I . Four histologic growth pattems
2. Three nuclear (anaplasia) grades
3. Summation of two scores

Gaeta (5)

1. Four histologic growth pattems
2. Four nuclear grades
3. Grade both features and assign highest score
(either growth pattem or nuclear grade)

MD Anderson (7)

Four grades depending on proportion of tumor forming
glandular structure (somewhat analogous to Broder's
approach to grading)

1. All grading systems identify a minority subset of poorly
differentiated or high grade tumors with a high likelihood of
progression.
2. While the majority of prostate cancers fall in the middle or
intermediate group of histologic grades, current histologic grading systems are not reliable or accurate in differentiating tumors
likely to progress from the more indolent or slow proliferating
neoplasms.
3. Well differentiated adenocarcinomas can also be segregated by histologic appearance. This small subset generally replicates slowly, and progression, if it occurs, is only after extended intervals. When well differentiated neoplasms are focal,
confirmation of stage A-l "incidental" neoplasms is appropriate. Since an adequate tissue sample is required to insure that the
neoplasm is tmly focal, needle tissue cores or aspirates can be
excluded as methods of diagnosing stage A-l cancers.
The development of histologic grading schemes has contributed to the clinical care of patients with prostate cancer (10).
Nevertheless, the problems outlined above are major deficiencies in determining the biologic potential of each cancer and deciding appropriate therapy.

Histologic Definitions of Localized
Prostate Adenocarcinoma
Focal or incidental (stage A-l) prostate cancer varies greatiy
with the patient's age and the type of surgical procedure (transurethral resection of the prostate [TURP] versus prostatectomy)
(II). The incidence of focal prostate cancer in autopsy studies
varies from 4% in the third decade to 80% in the ninth decade

Classification of Prostate Adenocarcinoma—Peters & Crissman 9

Table 2
Staging Designations for Carcinoma of the Prostate
Clinical Stage
Modified

Description

Jewett (25)

TNM (26)

Clinically unsuspected
incidental histologic finding
Focal, well differentiated
Diffuse, high grade

A
A-l
A-2

T-i
T-Ia
T-lb

Risk recognized clinically
Tumor confined to one lobe
Tumor in both lobes

B
B-l
B-2

T-2
T-2a
T-2b

C

T-3 to T-4
T-3

Periprostatic spread
Base of seminal vesicle
Base of seminal vesicle and/or
other structure
Distant metastases
Pelvic lymph node
Bones, lung, etc
Elevated acid phosphatase

T4
D
D-I
D-2
D-0

T-1-4, N-I-3, M-0-1
T-1-4, N-I, M-l
T-1-4, N-0-1, M-l
T-1-4, N-0-3, M-0

(12). Evaluation of prostatectomies for benign prostatic hypertrophy (BPH) reveals focal cancers in 3.5% to 24% of prostates
examined (13,14). Because of the small size of most stage A-l
carcinomas, step sections of all tissue are required (not routinely
performed in most pathology laboratories) to diagnose all small
latent neoplasms (15,16).
The separadon of focal (stage A-l) and diffuse (stage A-2) incidental adenocarcinomas discovered in transurethral prostate
resections is defined variably (17). Unfortunately, criteria for
separation of stage A tumors into A - l and A-2 are not completely agreed upon:
1. Three (18-20) to five (21) isolated foci of cancer has been
adopted by some investigators as the maximum allowable foci
(usually in TURP specimens) for stage A-l cancers.
2. Ofthe specimen involved by the malignant tumor, 5% of
area or less (as measured on the tissue slides) is used by other
investigators to define stage A-l (22,23).
3. One cc of tumor volume is used by yet another group of
investigators to separate stage A-l from more extensive stage
A-2 cancers (24).
All of these definitions attempt to apply a quantitative approach to differentiating the "incidental," presumably latent
cancer from diffuse adenocarcinomas thought to have a high
likelihood of progression. In addition, all authors factored the
histologic grade into the definition of occult cancer foci (stage
A-l). Since urologists and pathologists generally agree that
small or focal well differentiated tumors are unlikely to progress, they are appropriately classified as stage A-l (II). Conversely, since poorly differentiated focal cancers are likely to
progress, they are excluded from stage A-l regardless of tumor
extent. Staging designations commonly used for prostatic carcinoma include the modified Jewett (25) and the American Joint
Committee or tumor, node, metastasis (TNM) classifications
(26) (Table 2). A poorly differentiated focal incidental tumor is
considered to be stage A-2 according to this staging system. Un-
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fortunately, little is known about the intermediate histologic
grade neoplasm which constitutes a sizable proportion of these
"early" cancers. This is a major deficiency in current histologic
grading systems and is not addressed in most studies.
Golimbu et al (21) found that most unsuspected prostate carcinomas are diffuse (stage A-2). They also observed that patients
with stage A-2 neoplasms had a higher frequency of lymph node
metastases than patients with either stage A-l or B-l cancers.
Stage A-l was defined in their study as five or fewer isolated foci
(chips in TUR specimens) with a well-differentiated histologic
pattem. Any tumor with a poorly differentiated tumor grade was
classified as stage A-2. Blute et al (24) studied 23 untreated patients who were less than 60 years of age with stage A cancer.
Two ofthe eight classified as stage A-2 (greater than 1 cc or high
grade histology) progressed. Four of the 15 classified as stage
A-l also progressed after an average interval of 10.2 years. Cantrell et al (23) followed 117 patients with stage A cancer and determined that the cancer seldom progressed in patients with less
than 5% of surface area examined containing foci of well differentiated tumor histologies (Gleason score 2-4). Conversely, the
cancer progressed in 32% of patients with greater than 5% surface area and in 17% with a histologic grade greater than
Gleason score 4 (23). A follow-up study of the same patient population restricted to stage A-l tumors (less than 5% of surface
area and Gleason score 2-4 histology) showed that eight of 50
(16%) patients at risk for eight years or longer developed disease
progression (27). The authors concluded that stage A-l disease
carried substantial risk, but only after prolonged periods of follow-up, an important consideration in younger patients. The
Mayo Clinic study also demonstrated that in the long term patients with stage A-l neoplasms developed a substantial proportion of clinically significant cancers (24).

Biopsy Techniques
Tissue or cellular sampling of prostatic adenocarcinoma is
cmcial for confirmation of diagnosis. Optimum tissue sampling
must provide accurate diagnosis with minimal morbidity. Accuracy is critical, and the need for early diagnosis requires identifying smaller and smaller foci of cancer. The American College of Surgeons classified 22.9% of patients in clinical stage A
in their 1978 survey and 27.2% in the 1983 survey. Pathologic
confirmation of diffuse infiltrative neoplasms is usually not a
significant problem, but biopsy of tumor nodules (stage B-1) and
suspected tumor identified by ultrasound often proves to be difficult (28).
Needle core biopsy and needle aspirate cytology are the most
common metbods of sampling. Needle aspirate biopsy has
achieved considerable popularity in the past decade because of
decreased patient morbidity, although core needle biopsy techniques have the advantage of providing tissue for histologic examination. Interpretation of needle aspirate biopsy requires
skilled personnel, but in experienced hands accuracy is comparable to that of core needle biopsies (29-32) (Table 3). Grading
appears to be more reproducible in tissue sections from core
biopsies.

Classification of Prostate Adenocarcinoma—Peters & Crissman

Table 3
Accuracy of Needle Aspirate Biopsy in Diagnosis of Prostate Carcinoma

Study
Carter et al (32)
Epstein (29)
Kline et al (30)
Chodak etal (31)
Total

Total
Patients
IIO
1 IX
540
75

Malignant
Biopsy
Cytology
Confirmed
H- FNA Malignant -l57
42
170
19
2SS*

48 (86%)
37 (90%)
142 (92%)
12 (86%)
239 (90%)

Biopsy
Confirmed
Benign
8 (14%)
4 (9.7%)
12 (7.8%)
2(14%)
26(10%)

Unsatisfactory
or No Biopsy
1
I
16
5
23

*Lc.ss patients with unsatisfactory or no biopsy.
FNA = fine needle aspirate.

Table 4
Probability of Diagnosis of Carcinoma in TUR Prostate by Tissue Examined
Patients with
Suspected
Neoplasm

Number of
Carcinomas

Vollmer(33)

711

61 (8.6%)

Moore et al (34)*

151

39 (25.8%)

Murphy et al (35)

383

66 (17.2%)

6gt

65 (14.2%)

12-15 g
8 blocks§

Study

Rohr (36)

457

Proportion of
Specimen
.Saiiipied

Result

5 blocks
10 blocks
95% specimen
63% specimen
26% specimen

90% Gleason 3,4,5
98% Gleason 3,4,5
1 chip with Cat
3 chips with Ca
10 chips with Ca
100% stage A-2
90% stage A-l
82% Ca 1 chip
95% Ca 3-5 chips
100% Ca > 5 chips

*Consecutive cases.
t95% probability
tAverage l.5g/block.
§Average 1.6 g/block.
Ca = cancer

Transurethral resections of prostate occasionally reveal unsuspected adenocarcinoma. The incidence of stage A (especially A-I) tumors is dependent on patient age, tumor size,
and completeness of the pathology examination. The latter two
parameters are extremely important in identifying stage A-l tumors. Urologists and pathologists require variable amounts of
TUR tissue for histologic examination (Table 4). Several studies
have evaluated the relationship of the amount of tissue examined
to the sensitivity of detecting small or "early" A - l adenocarcinomas (33-37). These reports confinn that six to eight blocks
of approximately 1.5 g of tissue each is adequate to detect almost
all high grade and/or diffuse stage A-2 cancers. To identify
small foci of stage A-l tumors, almost all of the specimen must
be examined. Whether or not it is clinically relevant to diagnose
each of the small A-l nodules of neoplasm is a major issue. We
think it is relevant to identify stage A - l carcinomas in the
younger age group. These small foci of neoplasm appear to result in clinically significant cancers after many years.
The zonal distribution of prostate cancer is important in deciding the type of biopsy required for diagnosis. The anatomic
division of the prostate can be divided into central, transitional,
and peripheral zones (38). The majority of prostate cancers arise
in the peripheral zone (38,39), a region not usually included in
most TUR specimens. Only rarely do cancers arise in the central
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zone, and some evidence shows that these may have a different
biologic behavior (38). The transitional zone may serve as a barrier to neoplasms arising in the peripheral portion of the gland.
Only after extensive invasion is the transitional zone infiltrated
and the central zone involved by cancer. Rarely, neoplasms arise
in nodules of hyperplasia and develop primarily in the transitional zone of the gland (38). Thus, TURP does not resect portions of the gland in which the majority of cancers arise. Continued improvement in identifying asymptomatic "early"
cancers requires demonstration of nodules by physical examinadon and ultrasound, with directed needle biopsies.

DNA Analysis
The biologic behavior of prostatic adenocarcinoma is highly
varied (40). Pathologic staging and histologic grading are the
traditional means of predicting prognosis for patients with prostatic carcinoma (3,8). Poorly differentiated carcinomas progress
rapidly, but patients with well differentiated neoplasms may
have prolonged survival. With moderately differentiated
neoplasms, some patients do well but some die from their
tumors (41).
Chromosome analysis and DNA quantitation studies in various tumors show that malignancy is often associated with devia-
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tions from normal ploidy (42,43). The normal human somatic
cell contains 46 chromosomes (23 pairs) and is referred to as
diploid. A cell with fewer or more than 46 chromosomes is described as aneuploid (hypodiploid or hyperdiploid, respectively). Although identification of individual chromosomes is
possible only during metaphase, nuclear DNA content can be
measured on interphase cells, independent of the proliferative
activity ofthe tumor. Quantitative measurement of nuclear DNA
content is accomplished by one of two methods, the FeulgenSchiff technique or the use of fluorescent dyes such as propidium iodide (43). These stains bind to normal DNA in a
stoichiometric fashion, with the intensity of staining proportional to the DNA content. Thus, the DNA content in tissue sections can be determined by static cytometry using computer assisted image analysis. DNA content in tumor nodules can be
measured by flow cytometry (FCM) using disaggregated tumor
specimens of single cells in suspension.
Digital image analysis is a new, evolving approach to quantitative DNA cell analysis. Nuclear DNA content can be determined on archival pathologic specimens as well as on small
tissue samples. The variable amount of tumor often admixed
with nonneoplastic tissue in needle biopsies makes microscopic
image analysis an effective means of assessing DNA content in
prostatic adenocarcinoma. Nuclear DNA content assessed by
image analysis has also been shown to correlate well with flow
cytometric DNA measurements (44-46).
Several studies have utilized FCM to assess nuclear ploidy
whereas others have utilized static cytometry or image analysis
for assessment of nuclear DNA content. Using Feulgen-stained
nuclei and slide cytophotometry, Zetterberg and Esposti (47)
found that well differentiated tumors were predominantly
diploid and that poorly differentiated tumors were primarily hyperdiploid or aneuploid. Patients with moderately differentiated
tumors had either 1) diploid tumors or 2) aneuploid or hyperdiploid tumors. These investigators subsequently examined
tissues from 43 patients diagnosed with prostatic carcinoma up
to 15 years earlier (48). All patients had been treated with estrogen therapy. Patients with diploid range DNA content had a
good response to estrogen, whereas those with aneuploid DNA
tumors had a poor response to estrogen and thus decreased survival. Similarfindingshave been reported by Tavarres et al (49)
and Seppelt and Sprenger (50).
FCM was applied to prostate cancer in 1977 by Bichel et al
(51). Nuclei obtained from fine needle aspirates were examined
in 50 patients with BPH or prostate carcinoma. They found primarily diploid or diploid plus tetraploid populations in patients
with BPH. In patients with prostate carcinoma, well differentiated tumors were primarily diploid and poorly differentiated tumors had a higher DNA content with cell populations in the
tetraploid and octoploid range. Moderately differentiated tumors fell into two groups: those with no or few tetraploid cells
(similar to well differentiated carcinomas), and those with a high
percentage of tetraploid and octoploid cells (similar to poorly
differentiated tumors).
Ronstrom et al (52) studied 500 patients with suspected prostate carcinoma who underwent transrectal fine needle aspiration
biopsy. The aspiration cytology revealed 301 specimens interpreted as benign, 33 suspicious for carcinoma, and 166 diag-
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nostic of carcinoma. The 166 carcinomas revealed 45 (27%)
diploid tumors, 75 (45%) tetraploid tumors, and 46 (28%)
aneuploid tumors. The incidence of aneuploidy was inversely
related to tumor differentiation. Thus poorly differentiated tumors were most likely aneuploid (77%), and well differentiated
tumors were most likely diploid (56%). As expected, moderately differentiated tumors had an intermediate incidence of
diploid and aneuploid populations.
Stephenson et al (53) studied 82 patients with stage D-1 disease by FCM using cells from the lymph node metastases. Approximately 10% of patients had uninterpretable histograms.
The median survival was five years for patients with aneuploid
tumors and 8.8 years for those with diploid tumors. Winkler et
al (54) evaluated prostatic tissue from 91 patients with stage D-1
disease undergoing radical prostatectomy. A total of 87% of the
tumors were diploid (and/or tetraploid) and 13% were
aneuploid. Only 15% of the diploid tumors progressed, whereas
75% of aneuploid tumors progressed. In a similar study, Lee et
al (55) evaluated 88 patients undergoing radical prostatectomy
with negative lymph nodes. Flow cytometric DNA quantitation
showed 42% of the tumors to be diploid and 58% aneuploid. The
probability of disease-free survival at 60 months was 85% for
diploid tumors and 9% for aneuploid tumors. In addition,
aneuploidy correlated with a greater likelihood of seminal vesicle invasion by tumor and subsequent development of recurrent
disease.
At Henry Ford Hospital we have studied 44 patients with localized stage A or B prostate cancer who were surgically staged
and uniformly treated with '^'Iodine implantation. Feulgenstained nuclei were evaluated using image analysis. Twelve patients (27%) developed stage D-2 disease, with a mean followup of 69.5 months. The DNA pattem was diploid in 35 padents
(80%) and aneuploid in eight (18%). All of the aneuploid tumors
progressed to stage D-2 disease, whereas only 11% of the diploid
tumors progressed (P < 0.001 unpaired t test). Determination of
nuclear DNA content using image analysis provides objective
information tbat is directly related to prognosis. This confirms
the previously mentioned studies correlating tumor cell DNA
content with tumor progression (54,55).
Image analysis has many advantages compared to FCM. It allows DNA quantitation on small cell samples, as well as on paraffin-embedded archival samples or fresh tissue (56). Image
analysis is ideal for studying solid tumors since single cell suspensions are not necessary as in FCM. FCM of paraffin-embedded material is inferior to that obtained with fresh tissue, with
5% to 20% of histograms reported as uninterpretable (54,57).
Using image analysis of Feulgen-stained nuclei, all histograms
were evaluable with no cases excluded for inadequate staining or
preservation. Small amounts of tumor often admixed with normal glands can be identified by traditional morphologic observations and DNA quantitation restricted to the malignant cells.
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